Aprea Therapeutics
APRE
26 hedge funds and large institutions have $1.11M invested in Aprea Therapeutics in 2022 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 13 reducing their positions, and 8 closing their positions.
4,713% more call options, than puts
Call options by funds: $385K | Put options by funds: $8K
0.1% less ownership
Funds ownership: 0.46% → 0.36% (-0.1%)
21% less funds holding
Funds holding: 33 → 26 (-7)
27% less capital invested
Capital invested by funds: $1.52M → $1.11M (-$411K)
88% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 8
92% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$98.6K |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
+$54.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$54K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$40.7K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$39.3K |
| 4 |
Two Sigma Investments
New York
|
-$38.6K |
| 5 |
D.E. Shaw & Co
New York
|
-$37K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CM
26
Crestline Management
Fort Worth,
Texas
| – | -$36K | -2,441 | Closed |
|
|
VF
27
Virtu Financial
New York
| – | -$15K | -983 | Closed |
|
28
Citadel Advisors
Miami,
Florida
| – | -$16.8K | -944 | Closed |
|
29
Bank of New York Mellon
New York
| – | -$12K | -832 | Closed |
|
|
QT
30
Quantamental Technologies
White Plains,
New York
| – | -$9K | -568 | Closed |
|
31
Wells Fargo
San Francisco,
California
| – | -$408 | -23 | -77% |
|
APRE Hedge Fund Activity: Q3 2022 in Review
26 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Aprea Therapeutics (APRE) for Q3 2022, worth a combined $1.11M — down 27% from $1.52M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of APRE and 1 opened new positions — a net loss of 7 holders — while 13 trimmed existing stakes and 1 added.
The largest buyer was Millennium Management, adding an estimated $98.6K. The largest seller was Jane Street, exiting entirely with an estimated $54K sold.
- 26 institutional investors held Aprea Therapeutics (APRE) as of Q3 2022, down from 33 in Q2 2022.
- Funds reported $1.11M of Aprea Therapeutics stock for Q3 2022, down 27% quarter-over-quarter.
- 1 fund opened new Aprea Therapeutics positions in Q3 2022 and 8 closed out, a net change of -7 holders.
- The largest Aprea Therapeutics buyer in Q3 2022 was Millennium Management, an estimated $98.6K added.
- The largest Aprea Therapeutics seller in Q3 2022 was Jane Street, an estimated $54K sold.
Based on aggregated 13F filings for Q3 2022.